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Elsevier Taiwan LLC. Open access under CSummary Advanced hepatocellular carcinoma has a poor therapeutic outcome and treat-
ment options are limited. Sorafenib, an orally active multikinase inhibitor, is the only systemic
drug that has been shown to provide survival benefits in randomized control studies. However,
the gains in survival are modest and new treatment strategies are needed. We report here the
case of a patient with advanced hepatocellular carcinoma who had an impressive response to a
combination of sorafenib and radiotherapy. The treatment was well tolerated with no unex-
pected toxicities. Post-treatment imaging showed a satisfactory partial response with regres-
sion of the tumor by more than 50%.
Copyright ª 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy So-
ciety of Taiwan. Published by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third cause of cancer-related death in the
world (responsible for one million deaths per year) [1]. Inof Gastroenterology, Cheng-
eng-Hsin Street, Taipei 112,
com (C. Yeh).
4.01.005
stroenterological Society of Taiw
C BY-NC-ND license.Taiwan, HCC is the leading cause of cancer death, with
approximately 8000 new cases diagnosed and 7000 deaths
occurring annually. The 5-year survival rate of patients with
HCC is less than 10%, even with aggressive conventional
treatment. The treatment options for HCC are either
curative or palliative. Curative treatments, which achieve
the best outcomes, include liver resection and trans-
plantation, whereas palliative treatments include tumor
ablation, embolization, radiotherapy, and chemotherapy
[2]. When aggressive treatments fail, there is currently no
effective salvage treatment available. Clinical trials ofan and The Digestive Endoscopy Society of Taiwan. Published by
26 B.-L. Yang et al.multikinase inhibitors, such as sorafenib, have given
impressive results, with a moderate improvement in sur-
vival for advanced HCC in patients with ChildePugh grade A
cirrhosis [3]. However, there are limited options for the
management of HCC in patients with ChildePugh grade B
cirrhosis. We report here the case of a 68-year-old man with
advanced HCC related to hepatitis C and ChildePugh grade
B cirrhosis. This patient was successfully treated with sor-
afenib combined with radiotherapy.
Case report
A 63-year-old Chinese man with a history of chronic hepa-
titis C without regular follow up presented to our emer-
gency department with right upper quadrant abdominal
pain and general weakness. A physical examination showed
hepatosplenomegaly with abdominal tenderness and an
abdominal ultrasound scan showed liver cirrhosis with sus-
pected liver tumors. He was admitted to our gastrointes-
tinal ward on November 3, 2010 for further management.
His a-fetoprotein level was elevated (1032 ng/ml); howev-
er, his liver profile was ChildePugh grade B. Imaging studies
(abdominal magnetic resonance imaging) showed multiple
T1W1-low and T2W1-high intensity lesions of variable sizes
with early contrast enhancement over the whole liver
except for segments 1 and 5, and extensive tumor thrombus
involving the portal venous system, both hepatic veins, and
extending into the inferior vena cava. HCC was diagnosed
on the basis of his hepatitis C status with typical radiolog-
ical findings and raised serum a-fetoprotein level. He had a
European Cooperative Oncology Group performance status
1, a Barcelona Clinic Liver Cancer (BCLC) [4] classificationFigure 1 Computed tomography scans of our patient with hepato
proton beam therapy (A) and that from standard X-rays using the sam
lines are represented in red, yellow, light blue, and dark blue, res
pink. The protocol required the PTV to be encompassed by the 95%
vein. GTV Z gross tumor volume.stage C, and Cancer of the Liver Italian Program score 2. He
was given Duragesic (fentanyl transdermal) for a short
period to control his pain. Chemoembolization was not
offered due to the extensive macrovascular involvement.
Palliative radiation therapy (three-dimensional
conformal radiotherapy) was given 5 days per week at
1.8 Gy per day to the portal vein and tumor of the right lobe
for 28 fractions to a total dose of 50.4 Gy; treatment with
sorafenib (400 mg per day) was started on December 10,
2010. Fig. 1 A1,B1 and A2,B2 shows the dose distribution for
the tumor, portal vein, and surrounding organs and tissues.
The patient’s symptoms improved gradually with no
abdominal pain and his appetite improved. The follow-up
examination 6 months later indicated an early response,
with a dramatic reduction in the size of the liver masses
(8 cm to 3 cm) and a decrease in the a-fetoprotein level. He
experienced manageable side-effects of mild diarrhea,
itching of the skin with red papules over his scalp, Grade
2e3 hand and foot skin reactions, lesser control of hyper-
tension, and some hair loss. On completion of 16 months of
treatment he had ongoing marked clinical, radiological, and
biochemical responses (Figs. 2e4).
Discussion
Sorafenib is an orally active multikinase inhibitor that has
been shown to affect tumor cell proliferation and tumor
angiogenesis. It inhibits molecular components of the
RafeMEKeERK signaling pathway, abrogating tumor growth
and vascular endothelial growth factor receptors (VEGFR)
1, 2 and 3, and endothelial growth factor receptors PDGFR-
b, thus inhibiting neoangiogenesis [5]. Sorafenib emergedcellular carcinoma showing dose distribution of radiation from
e beam arrangement (B). The 100%, 95%, 80%, and 50% isodose
pectively. The planning target volume (PTV) is represented in
dose envelope. (A1), (B1) On liver tumor. (A2), (B2) On portal
Figure 2 Changes in laboratory data over time after treat-
ment with sorafenib and radiotherapy. AFP Z a-fetoprotein;
ALK-P Z serum alkaline phosphatase; ALT Z serum alanine
aminotransferase; AST Z serum aspartate aminotransferase;
T-Bilirubin Z total bilirubin.
Treatment of advanced hepatocellular carcinoma 27as the first effective systemic treatment in HCC after 30
years of research and is currently the standard of care for
patients with advanced tumors. Following an initial Phase II
study showing a signal of efficacy [3], a large double-
blinded placebo-controlled Phase III investigation wasFigure 3 Effect of treatment with sorafenib and radiotherapy e
Pretreatment and post-treatment in arterial phase. Part (B) also
(arrow); (C), (D) pretreatment and post-treatment in delayed phas
vein after treatment (arrowhead).conducted, leading to positive survival results. In this trial,
the benefit of sorafenib was to increase the median overall
survival time from 7.9 months in the placebo group to 10.7
months in the sorafenib group (hazard ratio Z 0.69; 95%
confidence interval 0.55e0.87; p Z 0.00058), which rep-
resents a 31% decrease in the relative risk of death.
The panel of experts recommends using sorafenib as the
standard systemic treatment for HCC. It is indicated for
patients with well-preserved liver function (ChildePugh
class A) and with advanced tumors of BCLC class C [6]. No
clear recommendation can be made in patients of Child-
ePugh class B liver function. Sorafenib is currently being
tested in the adjuvant setting after resection or complete
local ablation for early stage disease, in combination with
chemoembolization for intermediate stages [7], in combi-
nation with erlotinib or systemic doxorubicin in advanced
stages, and as a first-line treatment in ChildePugh B class
patients.
Historically, radiotherapy has always played a limited
part in the treatment of HCC as a result of a lack of high
evidence level data, especially randomized controlled tri-
als. The low tolerance of the liver and the subsequent risk
of radiation-induced liver disease have posed obstacles to
including radiotherapy in the routine treatment of HCC [8].valuated by abdominal magnetic resonance imaging. (A), (B)
shows decreased tumor size in arterial phase after treatment
e. Part (D) also shows decreased tumor thrombus in the portal
Figure 4 Effect of treatment with sorafenib and radiotherapy evaluated by abdominal magnetic resonance imaging. (A) Tumor
thrombus in the inferior vena cava before treatment in delayed phase; (B) decreased tumor thrombus in the inferior vena cava
after treatment (arrow); (C) tumor thrombus in the portal vein before treatment in coronal view; and (D) decreased tumor
thrombus in the portal vein after treatment (arrow).
28 B.-L. Yang et al.However, radiotherapy has undergone major technological
improvements over the last few decades, including diag-
nostic imaging, radiotherapy planning techniques (three-
dimensional conformal radiotherapy, intensity-modulated
radiotherapy, and stereotactic body radiosurgery), and
image-guided radiotherapy to detect to the exact position
of the tumor at the time of treatment so that higher doses
can be targeted to the tumor while minimizing exposure to
normal liver tissue. The evidence supporting radiotherapy
as a safe and efficacious option for the treatment of HCC
continues to grow and is summarized in Table 1 [9].
Radiotherapy is now an important option in patients with
unresectable HCC or with portal vein thrombosis [8].
Preclinical studies have documented improved outcomes
through synergistic antitumor activity with the combination
of VEGF or VEGFR inhibitors and irradiation, with the
combination resulting in a longer delay in tumor growth and
higher local tumor control than either treatment alone [8].
The mechanisms underlying the additive effect of these
modalities are complex and include decreased tumor hyp-
oxia and the radiosensitization of endothelial cells. Anti-
angiogenic drugs result in a relative normalization of blood
flow in tumors, with a more efficient delivery of oxygen andtherapeutic agents to the targeted malignant cells.
Therefore increasing the oxygenation of tumors would be
expected to improve their radiation response. However,
evidence for the clinical use of this combined treatment in
patients with HCC is lacking. Our patient tolerated the
combined regimen well, with a reduction in tumor volume
of more than 75%, reduced tumor thrombus in the portal,
hepatic, and inferior vena cava, and a decrease in a-feto-
protein level of 97% after treatment. According to the
response evaluation criteria [10] in solid tumors guidelines,
post-treatment imaging showed a partial response with
regression of the tumor by more than 50%.
In conclusion, improved outcomes have been shown with
sorafenib and radiotherapy for the treatment of advanced
HCC, as seen in the case reported here. Further studies
addressing the combination of these modalities are war-
ranted to confirm the efficacy, toxicity, and optimal
sequencing of this treatment.Conflicts of interest
All contributing authors declare no conflicts of interest.
Table 1 Summary of treatment outcomes of three-dimensional conformal radiotherapy (3D-CRT) trials for hepatocellular
carcinoma.
Reference n ChildePugh
A and B (%)a
Tumor size Total dose
(Gy) (number
fraction)
Response
(%)
2-yr
LC (%)
1-yr
OS (%)
2-yr
OS (%)
3-yr
OS (%)
5-yr
OS (%)
Mornex et al
(2006);
(Phase II)
25 A 64 (16/25)
B 44 (11/25)
1 nodule
<5 cm;
2 nodules
<3 cm
66
(2 y/fx  30)
92; CR 80;
PR 12
Kim et al
(2005)
59
35 (s/p RFA
TACE)
PVT (þ) 30e54 45.8 40.7 20.7
Seong et al
(R) (2003)
158 A 74; B 26 51% PVT(þ)
49% PVT(e)
75% <10 cm
25% >10 cm
67.1 59.4 30.5 9
Liu et al
(2004)
44 A 72 (32/44);
B 27 (12/44)
6e25 cm 40e60 61; CR 13;
PR 25e78
60.5 40.3 32 9e19
Bush et al
(2004)
(Phase II)
37 5.6 cm
(1.5e10 cm)
42 (15 fx) 75 55
CR Z complete response; fx Z fractions; LC Z local control; OS Z overall survival; PR Z partial response; PVT Z Portal vein
thrombosis; R Z retrospective; RFA Z Radiofrequency ablation; SD Z stable disease; s/p Z status post; TACE Z Transarterial che-
moembolization.
Note. From “Radiotherapy and hepatocellular carcinoma: update and review of the literature,” by S. Ursino, C. Greco, F. Cartei, C.
Colosimo, A. Stefanelli, B. Cacopardo, et al, 2012, Eur Rev Med Pharmacol Sci 16, pp. 1599e604. Copyright 2012, European Review for
Medical and Pharmacological Sciences. Adapted with permission.
a ChildePugh B score patients are more likely to develop radiation-induced liver disease.
Treatment of advanced hepatocellular carcinoma 29References
[1] Bosch FX, Ribes J, Dı´az M, Cle´ries R. Primary liver cancer: world-
wide incidence and trends. Gastroenterology 2004;127:S5e16.
[2] Bruix J, Sherman M. Management of hepatocellular carci-
noma. Hepatology 2005;42:1208e36.
[3] Abou-AlfaGK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A,
et al. Phase II study of sorafenib in patients with advanced he-
patocellular carcinoma. J Clin Oncol 2006;24:4293e300.
[4] Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma:
the BCLC staging classification. Semin Liver Dis 1999;19:329e38.
[5] Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in
cancer: therapeutic potential of targeting the Raf/MEK/ERK
signal transduction pathway. Semin Oncol 2006;33:392e406.
[6] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF,
et al. Sorafenib in advanced hepatocellular carcinoma. N Engl
J Med 2008;359:378e90.[7] Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, et al.
Three-dimensional conformal radiotherapy of unresectable
hepatocellular carcinoma patients for whom transcatheter
arterial chemoembolization was ineffective or unsuitable. Am
J Clin Oncol 2006;29:568e75.
[8] Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treat-
ment of solid tumors using radiotherapy and molecular tar-
geted agents. J Clin Oncol 2003;21:2760e76.
[9] Ursino S, Greco C, Cartei F, Colosimo C, Stefanelli A,
Cacopardo B, et al. Radiotherapy and hepatocellular carci-
noma: update and review of the literature. Eur Rev Med
Pharmacol Sci 2012;16:1599e604.
[10] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH,
Sargent D, Ford R, et al. New response evaluation criteria in
solid tumours: Revised RECIST guideline. European Journal of
Cancer 2009;45:228e47.
